FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma

South San Francisco, CA -- February 26, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news